BSE Live
Jan 27, 14:35Prev. Close
1970.75
Open Price
1905.55
Bid Price (Qty.)
1985.00 (2)
Offer Price (Qty.)
1986.25 (2)
NSE Live
Jan 27, 14:35Prev. Close
1967.70
Open Price
1968.40
Bid Price (Qty.)
1985.10 (22)
Offer Price (Qty.)
1985.90 (19)
| Cash Flow of Glenmark Pharma (in Rs. Cr.) | Mar 05 | Mar 04 | |
| 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 86.94 | 52.54 | |
| Net CashFlow From Operating Activities | 10.11 | 23.84 | |
| Net Cash Used In Investing Activities | -203.87 | -42.59 | |
| Net Cash Used From Financing Activities | 296.27 | 21.48 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 102.51 | 2.72 | |
| Cash And Cash Equivalents Begin of Year | 6.77 | 4.05 | |
| Cash And Cash Equivalents End Of Year | 109.28 | 6.77 |
04.12.2025
Glenmark Consolidated September 2025 Net Sales at Rs 6,046.87 crore, up 76.1% Y-o-Y
24.11.2025
Glenmark Standalone September 2025 Net Sales at Rs 1,538.66 crore, down 41.63% Y-o-Y
27.05.2025
Glenmark Standalone March 2025 Net Sales at Rs 2,009.49 crore, down 6.46% Y-o-Y
04.03.2025
Glenmark Consolidated December 2024 Net Sales at Rs 3,387.55 crore, up 35.14% Y-o-Y
08.07.2022
Glenmark Pharmaceuticals Q1 PAT may dip 41.8% YoY to Rs 178.4 cr: Prabhudas Lilladher
14.04.2022
Glenmark Pharmaceuticals Q4 PAT may dip 20.1% YoY to Rs 186.8 cr: Prabhudas Lilladher
13.01.2022
Glenmark Pharmaceuticals Q3 PAT seen up 17.8% YoY to Rs 292.4 cr: Prabhudas Lilladher
06.10.2021
Glenmark Pharmaceuticals Q2 PAT seen up 18.4% YoY to Rs 269.5 cr: Prabhudas Lilladher
31.05.2019
Glenmark Pharma wilts 3% on muted Q4 show, CLSA downgrades to sell
09.02.2018
Glenmark Pharma tanks 9% after disappointing Q3 earnings, US pricing pressure to continue
28.07.2017
31.07.2015